索托维单抗在有进展为重症 COVID-19 疾病高风险的低龄儿科患者中的应用。
Sotrovimab Use in Young Pediatric Patients at High Risk of Progression to Severe COVID-19 Disease.
作者信息
White Elizabeth, Legg Amy, Bogart Alexandra, Graham Nicolette, Jebreen Faten, Clark Julia E
机构信息
Infection Management and Prevention Service, Queensland Children's Hospital, Brisbane, Queensland, Australia.
Metro North Hospital and Health Service, Herston Infectious Diseases Institute, Brisbane, Queensland, Australia.
出版信息
J Pediatric Infect Dis Soc. 2023 Apr 28;12(4):242-245. doi: 10.1093/jpids/piad020.
This retrospective analysis describes the administration of sotrovimab in 32 children (22 aged 12-16 years old; 10 aged 1-11 years old) who were at high risk of deterioration to severe COVID-19 disease. We provide dosing suggestions and demonstrate the feasibility of sotrovimab use in the younger pediatric population (<12 years old and <40 kg).
这项回顾性分析描述了在32名有恶化成重症COVID-19疾病高风险的儿童（22名年龄在12至16岁；10名年龄在1至11岁）中使用索托维单抗的情况。我们提供了给药建议，并证明了索托维单抗在年龄较小的儿科人群（<12岁且<40千克）中使用的可行性。
Zotero 插件